Group 1: Company Updates - ChaoYing Electronics has adjusted the investment amount for its AI computing power high-end printed circuit board expansion project from 1.468 billion RMB to 3.315 billion RMB, aiming to meet stronger demand for high-end PCB products and enhance overseas production capabilities [2] - Baihua Pharmaceutical and Siwei Control have both terminated their plans for control change due to a lack of consensus with the transaction parties, with their stocks set to resume trading on January 7, 2026 [3] - Aihui Long has signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products through its strong sales channels in emergency, brain disease diagnosis, and pediatrics [10] Group 2: Performance Forecasts - Zhongtai Co. expects a net profit of 420 million to 480 million RMB for 2025, recovering from a loss of 77.96 million RMB in the previous year due to improved operations of its subsidiary [5] - Lier Chemical anticipates a net profit of 460 million to 500 million RMB for 2025, representing a year-on-year growth of 113.62% to 132.19% due to increased demand for its products [5] Group 3: Financing and Restructuring - Zhejiang Xiantong plans to issue A-shares to no more than 35 specific investors, raising up to 1.05 billion RMB for smart manufacturing projects and working capital [7] - Longjing Environmental Protection has received acceptance from the Shanghai Stock Exchange for its securities issuance application, pending further approvals [8] Group 4: Strategic Partnerships - Fushite has signed a strategic cooperation agreement with Jiangxi Copper Group to enhance collaboration in mining equipment maintenance and expand overseas market development [15] - Pro Pharmaceutical has entered into a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., focusing on long-term collaboration in innovative drug research and outsourced production [15] Group 5: Market Activity and Stock Performance - Jia Mei Packaging's stock price increased by 230.48% from December 17, 2025, to January 6, 2026, prompting a temporary suspension for investigation due to significant price volatility [11] - Guosheng Technology's stock experienced a 370.20% increase from October 31, 2025, to January 6, 2026, leading to a suspension for review due to potential irrational market behavior [20]

今日焦点 20CM两连板三博脑科：目前不涉及脑机接口产品的研发、生产及销售 三博脑科公告称，公司股票于2026年1月5日、1月6日连续两个交易日内收盘价格涨幅偏离值累计超过 30%，属于股票交易异常波动情形。公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提 供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调 控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 2连板翔宇医疗：截至2025年末脑机接口相关产品尚未实现规模化销售 翔宇医疗发布异动公告，近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价涨幅较 大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言语、吞咽等康复全场 景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面的投入，目前在技 术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至2025年末，相关产品 尚未实现规模化销售，营收占比较小。 6天4板中国卫通：目前股价已处于历史最高点，已严重脱离基本面存在短期大幅下跌的风险 中国卫通发布股票交易风 ...

Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO) [1] Group 1: Strategic Cooperation - The agreement establishes a strategic partnership between Pro Pharmaceutical and Xi'an New Tong, focusing on long-term collaboration in CDMO projects [1] - This collaboration is expected to enhance Pro Pharmaceutical's CDMO business competitiveness and facilitate its expansion in this sector [1] Group 2: Xi'an New Tong's IPO - Xi'an New Tong is currently preparing for an IPO on the Sci-Tech Innovation Board, with its application accepted on December 29, 2025, aiming to raise 900 million yuan [1]

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as custom manufacturing projects [2] Group 1 - The agreement does not involve substantial transactions and will not have a significant impact on the company's operating performance for the current year [2] - The future impact on the company's operating performance will depend on subsequent specific project agreements and their implementation [2]

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The agreement is based on principles of equality, mutual benefit, and complementary advantages [1]

智通财经APP讯，普洛药业(000739.SZ)公告，公司作为乙方与西安新通药物研究股份有限公司(简称"西 安新通"、甲方)近日签订了《战略合作框架协议》，旨在开展创新药研发与外包定制生产项目("CDMO 项目")的长期合作。 ...

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to collaborate in the fields of innovative drug research and development and contract development and manufacturing organization (CDMO) projects for a duration of ten years [1] Group 1: Agreement Details - The agreement aims to enhance the company's competitiveness in the CDMO business through complementary advantages [1] - This framework agreement does not involve specific transactions and will not have a significant impact on the company's operating performance for the current year [1] - The impact on future operating performance will depend on the signing and implementation of specific project agreements [1] Group 2: Intellectual Property and Responsibilities - During the collaboration, research results and related intellectual property will belong to Xi'an New Tong [1] - The company commits to using the relevant technologies and processes only within the scope of the cooperation and guarantees that the development results do not infringe on third-party rights [1] Group 3: Risks and Uncertainties - The specific cooperation matters will require separate agreements, and there is uncertainty regarding the ability to achieve substantial cooperation [1] - The progress of the collaboration may be affected by industry policies, market conditions, and other force majeure factors [1]

Core Viewpoint - The company, Pro Pharmaceutical (000739), has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The collaboration aims to expand the company's CDMO business and enhance its competitiveness in the CDMO sector [1]

证券代码：000739 证券简称：普洛药业 公告编号：2026-02 1.本次公司与合作方签署的《战略合作框架协议》，本着平等互利、优 势互补的原则，经友好协商，就研发与外包定制生产项目的合作关系达成共 识。具体项目合作事宜将由双方另行签署具体协议。 2.本次签署的《战略合作框架协议》对公司本年度经营业绩不会构成 重大影响，对公司未来年度经营业绩的影响将视公司与合作方后续签订的 具体项目协议以及实施情况而确定。 3.公司不存在最近三年披露的框架协议无进展或进展未达预期的情况。 一、战略框架协议签署概况 普洛药业股份有限公司(以下简称"公司"或"乙方")与西安新通药 物研究股份有限公司（以下简称"西安新通"或"甲方"）本着平等互利、 优势互补的原则，于近日签订了《战略合作框架协议》，旨在开展创新药 研发与外包定制生产项目（以下简称"CDMO项目"）的长期合作。 二、战略合作框架协议合作方基本情况 普洛药业股份有限公司 关于签署战略合作框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本次签署的《战略合作框架协议》仅为框架性协议，不涉及实质性交 易， ...

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as outsourced custom manufacturing projects [1] Group 1: Agreement Details - The agreement is a framework agreement and does not involve substantial transactions or constitute a major asset restructuring [1] - The collaboration is expected to benefit the company's CDMO (Contract Development and Manufacturing Organization) business expansion and enhance its competitive edge [1] Group 2: Financial Impact - The agreement is not expected to have a significant impact on the company's operating performance for the current fiscal year [1] - Future performance implications will depend on subsequent specific project agreements and their implementation [1]